Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Papi

Showing results (321-330 of 430) with videos related to

Pageof 43
Sort By:
European Journal of Internal Medicine|August 13, 2025
A person-centred clinical approach to the multimorbid patient with COPDBartolome R Celli, Leonardo M Fabbri, Abebaw M Yohannes, et al.
Thorax|January 17, 2014
Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPDAntonino Di Stefano, Gaetano Caramori, Adam Barczyk, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Journal of Asthma and Allergy|December 28, 2020
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung FunctionIan D Pavord, Salman Siddiqui, Alberto Papi, et al.
The European Respiratory Journal|January 13, 2018
Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?Kevin C Wilson, Jerry A Krishnan, Pawel Sliwinski, et al.
The European Respiratory Journal|March 17, 2017
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Marc Miravitlles, John R Hurst, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
Frontiers in Immunology|March 26, 2021
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 PatientsMarco Contoli, Alberto Papi, Luca Tomassetti, et al.
The European Respiratory Journal|September 11, 2017
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Peter M A Calverley, Richard K Albert, et al.
Pageof 43

Showing results (321-330 of 430) with videos related to

Sort By:
Pageof 43
European Journal of Internal Medicine|August 13, 2025
A person-centred clinical approach to the multimorbid patient with COPDBartolome R Celli, Leonardo M Fabbri, Abebaw M Yohannes, et al.
Thorax|January 17, 2014
Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPDAntonino Di Stefano, Gaetano Caramori, Adam Barczyk, et al.
The Lancet. Respiratory Medicine|February 3, 2025
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trialsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Journal of Asthma and Allergy|December 28, 2020
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung FunctionIan D Pavord, Salman Siddiqui, Alberto Papi, et al.
The European Respiratory Journal|January 13, 2018
Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?Kevin C Wilson, Jerry A Krishnan, Pawel Sliwinski, et al.
The European Respiratory Journal|March 17, 2017
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Marc Miravitlles, John R Hurst, et al.
Respiratory Medicine|January 25, 2024
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthmaAlberto Papi, Mario Castro, Jonathan Corren, et al.
Respiratory Medicine|March 2, 2025
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scoresClaus F Vogelmeier, Klaus F Rabe, Surya P Bhatt, et al.
Frontiers in Immunology|March 26, 2021
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 PatientsMarco Contoli, Alberto Papi, Luca Tomassetti, et al.
The European Respiratory Journal|September 11, 2017
Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineJadwiga A Wedzicha, Peter M A Calverley, Richard K Albert, et al.
Pageof 43